» Articles » PMID: 36249523

Targeted MicroRNA Profiling in Gastric Cancer with Clinical Assessement

Overview
Publisher Sciendo
Specialty Genetics
Date 2022 Oct 17
PMID 36249523
Authors
Affiliations
Soon will be listed here.
Abstract

Although several microRNAs (miRNAs) have been associated with gastric cancer there is still the need for identification of stable and validated biomarkers. The purpose of this study was to determine the alterations of a specific set of miRNA levels in gastric adenocarcinoma tissues to identify and validate gastric cancer-specific miRNAs using paired normal and tumor samples in an independent patient cohort. Gastric adenocarcinoma and normal stomach tissue samples of 20 patients who underwent surgery for gastric cancer were studied. The miRNA expression profiling was performed for eight miRNAs in a total of 40 tissue samples using quantitative reverse transcription polymerase chain reaction (RT-qPCR). Six out of these eight miRNAs, namely, miR-375-3p, hsamiR-129-5p, miR-196a-5p, miR-376c-3p, miR-34c-5p and miR-767-5p, were significantly underexpressed in malignant tissues of our cohort. Furthermore, the expression of miR-662 although not significantly different between normal and tumor tissues, was inversely associated with age ( = -0.440, = 0.049). The levels of miR-129-3p and miR34c-5p were correlated with an increase in the number of metastatic lymph nodes ( = 0.470, = 0.036; = 0.510, = 0.020), while and miR-376c-3p levels were negatively associated with smoking ( = 0.043). In addition, we found that the variability of miRNA expression in cancerous tissues was lower than that in normal tissues. Alterations in miRNA expression in gastric adenocarcinoma tissues in comparison to healthy tissues of each individual serves for identification of consistent biomarkers that can be used for development of diagnostic tools for gastric cancer.

Citing Articles

siRNA-based strategies to combat drug resistance in gastric cancer.

Khaleel A, Alshahrani M, Rizaev J, Malathi H, Devi S, Pramanik A Med Oncol. 2024; 41(11):293.

PMID: 39428440 DOI: 10.1007/s12032-024-02528-w.


Role of Some microRNA/ADAM Proteins Axes in Gastrointestinal Cancers as a Novel Biomarkers and Potential Therapeutic Targets-A Review.

Kalita A, Sikora-Skrabaka M, Nowakowska-Zajdel E Curr Issues Mol Biol. 2023; 45(4):2917-2936.

PMID: 37185715 PMC: 10136553. DOI: 10.3390/cimb45040191.


The miRNA125a-5p and miRNA125b-1-5p cluster induces cell invasion by down-regulating DDB2-reduced epithelial-to-mesenchymal transition (EMT) in colorectal cancer.

Zhu F, Wei J, He D, He J, Liu L, Hou H J Gastrointest Oncol. 2023; 13(6):3112-3122.

PMID: 36636074 PMC: 9830343. DOI: 10.21037/jgo-22-1222.


Identification of Differentially Expressed miRNAs in Porcine Adipose Tissues and Evaluation of Their Effects on Feed Efficiency.

Liao M, Ren Z, Miao Y Genes (Basel). 2022; 13(12).

PMID: 36553673 PMC: 9778086. DOI: 10.3390/genes13122406.

References
1.
Jansson M, Lund A . MicroRNA and cancer. Mol Oncol. 2012; 6(6):590-610. PMC: 5528350. DOI: 10.1016/j.molonc.2012.09.006. View

2.
Yan X, Luo Q, Zhou S, Pan W, Zhang L, Yang D . MicroRNA-375 reverses the expression of PD-L1 by inactivating the JAK2/STAT3 signaling pathways in gastric cancer. Clin Res Hepatol Gastroenterol. 2020; 45(5):101574. DOI: 10.1016/j.clinre.2020.10.015. View

3.
Ni H, Qin H, Sun C, Liu Y, Ruan G, Guo Q . MiR-375 reduces the stemness of gastric cancer cells through triggering ferroptosis. Stem Cell Res Ther. 2021; 12(1):325. PMC: 8180146. DOI: 10.1186/s13287-021-02394-7. View

4.
Morata-Tarifa C, Picon-Ruiz M, Grinan-Lison C, Boulaiz H, Peran M, Garcia M . Validation of suitable normalizers for miR expression patterns analysis covering tumour heterogeneity. Sci Rep. 2017; 7:39782. PMC: 5209713. DOI: 10.1038/srep39782. View

5.
Skrzypski M, Czapiewski P, Goryca K, Jassem E, Wyrwicz L, Pawlowski R . Prognostic value of microRNA expression in operable non-small cell lung cancer patients. Br J Cancer. 2014; 110(4):991-1000. PMC: 3929871. DOI: 10.1038/bjc.2013.786. View